Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Future of Money Movement: Indicators of Stablecoin Adoption

    As stablecoins evolve beyond cryptocurrency trading, certain market indicators can signal their integration into mainstream commerce.

    Read more

  • Navigating Compliance and Regulation in AI-Driven RCM

    While revenue cycle management may be primed for more efficient AI integration, significant compliance considerations remain.

    Read more

  • The Role of Private Equity in the Rise of High-Volume, Low-Price Fitness Clubs

    Discover how private equity is fueling the rapid expansion of high-volume, low-price fitness clubs—reshaping the industry with affordable memberships, innovative amenities, and data-driven growth strategies.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures